INTRODUCTION
sarcopenia, atrophy, Skeletal muscle disuse, muscle loss, chronic disease
SARCOPENIA, ATROPHY, TYPE 2 DIABETES MELLITUS, DISEASES, CHRONIC DISEASE
Skeletal muscle disuse in older adults increases the risk of falls, hospitalization, and chronic disease development and accelerates age‐induced muscle loss (sarcopenia) (Kehler et al., Metformin is a commonly prescribed and cost‐effective drug used to lower blood glucose in individuals with type 2 diabetes mellitus. Recently, metformin has gained traction to be considered as an alternate use therapeutic in treating a broad range of age‐related diseases (Check Hayden, Metformin is also well characterized to prevent cellular senescence and the senescence‐associated secretory phenotype (SASP) (Chen et al., Therefore, the purpose of this study was to determine the influence of metformin pre‐treatment on muscle ECM remodeling, macrophage content, and cellular senescence/SASP in older adults during bed rest, and a short‐term re‐ambulation period. We hypothesized that metformin would attenuate myofiber atrophy and cellular senescence/SASP and improve collagen remodeling during disuse and recovery in older adults.